TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

Hepatocellular carcinoma (HCC) is associated with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits. Here we assessed whether combining the TLR3 agonist: lysine-stabilized polyinosinic-polycytidylic-acid (poly-ICLC) with Sorafenib could enhance tumo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Ho, Victor, Lim, Tong Seng, Lee, Justin, Steinberg, Jeffrey, Szmyd, Radoslaw, Tham, Muly, Yaligar, Jadegoud, Kaldis, Philipp, Abastado, Jean-Pierre, Chew, Valerie
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694987/
https://ncbi.nlm.nih.gov/pubmed/26287667
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares